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Abstract
E74-like factor 5 (Elf5) has been associated with tumor suppression in breast cancer. How-
ever, its role in urothelial cancer (UC) is completely unknown. Immunohistochemistry (IHC)
and methylation specific PCR (MSP) were done to detect Elf5 expression level and its pro-
moter methylation. Results revealed that low expression of Elf5 on protein and mRNA levels
were associated with tumor progression, early relapse and poor survival. In vitro, down-
regulation of Elf5 can increase epithelial-mesenchymal transition (EMT). Aberrant Elf5
methylation was identified as major mechanism for Elf5 gene silence. Accordingly, restora-
tion of Elf5 by infection or demethylating treatment effectively reversed EMT processes. In
conclusion, we identified Elf5 as a novel biomarker of UC on several biological levels and
established a causative link between Elf5 and EMT in UC.
Introduction
The EMT affects critical steps of marked changes in cell adhesion, polarity and migratory by in-
terconverting epithelial cells into cells with mesenchymal / stem cell (SC) state [1,2,3]. EMT
and its reverse program, mesenchymal-epithelial transition (MET), were activated in tumour
cells and this progress enable these cells to acquire cellular traits associated with high-grade, in-
vasiveness and recurrence [3,4,5]. Given the complexity and dynamic nature of EMT, it is im-
possible to be maintained by a single signaling pathway. TGF-β, Wnt, Notch, Sonic Hedgehog,
EGF and FGF pathways have been proved to be important for governing these transitions in
cancer development and progression [2,3,6,7]. More recently, epigenetic modifications such as
methylation / demethylation have also been shown to be involved in EMT [8,9,10]. However,
the signaling mechanisms that induce and maintain this mesenchymal / SC state still remain
unclear.
Elf5 is a member of the epithelium specific subgroup of the large E-twenty-six (ETS) tran-
scription factor family. It has been proved as a key transcriptional determinant of breast cancer
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lineage by suppressing estrogen sensitivity in luminal cells and enhancing basal characteristics
in basal breast cancer cells [11]. More recent studies show Elf5 is not only as a key cell lineage
regulator, but also as a suppressor of EMT by repressing the transcription of Snail2 [12]. In ad-
dition, Elf5 gene silencing is triggered by dynamic promoter hypermethylation in the processes
of human placenta development and embryonic cell lineage formation [13,14]. However, the
roles of Elf5 in urothelial cancer (UC) development and progression remain undefined.
Bladder UC is the sixth most common cancer in the world with about 386,000 new cases in
2008 and estimated 150,000 deaths [15]. At the first diagnosis of UC, nearly 80% patients pres-
ent with non-muscle invasive bladder cancer (NMIBC) while the remainders with muscle inva-
sive diseases [16,17]. Of these patients with NMIBC, 50%–70% will have at least one
recurrence in 5 years, and more than 20% will exhibit muscle infiltration [18] and cause a mor-
tality rate up to 50% within 2 years of diagnosis [19]. The issue associated with UC is their
highly unpredictable potential for recurrence and progression. Therefore, we wished to deter-
mine whether epigenetic inactivation of Elf5 is associated with UC progression and early
recurrence.
Materials and Methods
Ethics statement, Patients and Samples
Cohort 1:
A total of 182 formalin-fixed paraffin-embedded bladder UC samples were obtained among
the 275 consecutive patients between 2004 and 2008 from the pathology departments of Tian-
jin Institute of Urology (Table 1). 10 contemporary formalin-fixed paraffin-embedded normal
urothelium (NU) were also obtained. Among the analyzed patients, 115 primary bladders UCs
underwent transurethral resection of bladder tumor (TURBT) (Cohort 1A) and the remained
67 patients underwent radical cystectomy (Cohort 1B). None of the primary patients received
any preoperative anticancer treatment. Follow-up information was obtained from the medical
Table 1. Clinical characteristics and ELF5 expression in cohort 1 patients.
Variable No. of ELF5 P
patients 10% >10%
Normal tissue 10 1 9 0.01
TCC 182 103 79
Age, years
<60 77 45 32 0.67
60 105 58 47
Tumor size, cm
<3 113 61 52 0.36
3 69 42 27
Tumor grade
G1–2 67 31 36 0.03
G3 115 72 43
Tumor stage
Ta-T1 146 77 69 0.03
T2-T4 36 26 10
Tumor occurrence
Primary 139 73 66 0.04
Recurrent 43 30 13
doi:10.1371/journal.pone.0117510.t001
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records of patients who fulfilled study inclusion criteria. In brief, patients presented postopera-
tively every 3 months for the first 2 years after therapy and semiannually thereafter. Recurrence
was defined as a new tumor observed in the bladder after TURBT. Recurrence-free survival
(RFS) was calculated as the time from TURBT to the date of recurrence. Disease-specific sur-
vival (DSS) was calculated as the time from radical cystectomy to the date of death from UC.
Mean follow-up was 49.4 months (range 6 to 90) and 56.4 months (range 6 to 106) in Cohort
1A and Cohort 1B, respectively.
Cohort 2:
A series of 10 NU and 50 UC tissues were obtained from retrospective record of Tianjin In-
stitute of Urology. These tissues were flash-frozen in liquid nitrogen and stored at -80°C be-
tween 2010 and 2013. There was no confirmed recurrence and death in the study.
The pathologic diagnoses and the clinic-pathologic factors of the two cohorts were estab-
lished based on the general guideline for primary bladder cancer as defined by the 2002 TNM
classification and 1973 WHO grading system by experienced pathologists. The study protocol
was approved by the ethics committee of Second Hospital of Tianjin Medical University, and
written informed consent for the use of the specimens from each patient enrolled was obtained
accordingly. All tissue samples and medical record data were anonymized prior to access and
analysis by the researchers.
Cell culture and treatment
The human bladder cell lines UROtsa, RT112, HT1376, J82 and T24 were originally obtained
from the ATCC. The cell line EJ was a gift from Dr. Ruifa Han (Tianjin Medical University,
China. He obtained the cell line from the ATCC). UROtsa was cultured in DMEM (Gibco,
Shanghai). HT1376 was cultured in Eagle’s Minimum Essential Medium (EMEM, ATCC).
Other cell lines were maintained in RPMI 1640 (Gibco, Shanghai). All culture mediums were
supplemented with 10% Fetal Bovine Serum (FBS, Gibco, Melbourne) and 1% penicillin/strep-
tomycin. Mycoplasma infection was regularly tested using the PlasmoTestTM (InvivoGen, San
Diego, CA). When necessary, cells were treated with 5μM 5-Aza-20-deoxycytidine (5-AZA,
Invivogen) according to previously determined concentration for 6 days of incubation [20,21].
RNA extraction and Quantitative RT-PCR
RNA was isolated using the GenElute (Sigma-Aldrich, Shanghai) according to the manufactur-
er’s instructions. Reversed transcription was performed using Transcriptor First Strand cDNA
Synthesis Kit (Roche, Shanghai). RT-PCR was performed on a BioRad iCycler iQ (Bio-Rad
Laboratories) PCR machine (Applied Biosystem) using SYBR Green Master Mix. The gene-
specific primer sets were used at a final concentration of 0.2μM and their sequences are listed
in S1 Table. Each sample was run and analyzed in triplicate.
Bisulfite-modification and MSP
Genomic DNA was obtained from tissue specimens using DNeasy Tissue Kit (Qiagen, Valen-
cia, CA) following the manufacturer’s protocol. The extracted DNA was treated with bisulfite
to convert unmethylated cytosines to uracils prior to methylation-specific polymerase chain re-
action (MSP) using EpiTect Bisulfite Kit (Qiagen) according to the manufacture’s instruction.
Modified DNA was amplified using MSP primers (S1 Table), which specifically recognized ei-
ther the unmethylated (product size 258 bp) or methylated (258 bp) Elf5 promoter sequence
after bisulphite conversion. Normal DNA from human appendix vermiformis was treated in
vitro with SssI methyltransferase (New England Biolabs, Beverly, MA) to generate a positive
control for methylated alleles [22].
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IHC staining
Paraffin-embedded sections (4μm) were deparaffinized and hydrated in xylene followed by
graded alcohols to water. Antigen retrieval was performed in 0.01 M citrate for twice 10 min in
a microwave oven followed by a 60-min cool down. Slides were then incubated with various
primary antibodies followed by Envision-plus labeled polymer-conjugated horseradish peroxi-
dase and DAB monitoring staining (Zhong Shan gold bridge, Beijing). Then, slides were coun-
terstained and dehydrated for viewing and imaging. Antibodies were: anti-Elf5 (Santa Cruz
Biotechnology, Santa Cruz, CA), anti-E-cadherin (Abcam, Cambridge, MA), anti-N-cadherin
(Abcam), anti-Vimentin (Abcam).
Scoring of IHC staining
Elf5 score: The entire section was evaluated by two respective observers being unaware of the
clinical data. The tumor cells were determined positive when a clearly visible staining was de-
tected in nucleus. NU tissues were included to be as internal controls. Percent of staining posi-
tive cell was graded as 1% to 100% with a 5% interval. Counted percents were rounded to the
nearest gears. A cut-off value of 10% was determined arbitrarily, and according to this value,
two groups (low and high Elf5 staining) were assigned.
Vimentin and E-cadherin score: Five random low magnification fields were selected, then
the proportion of positive region was determined by ImageJ program. Cut-off values were de-
termined by the median, according which, two groups (low and high expression)
were assigned.
Molecular cloning and viral infection
The pLEX plasmids (Open Biosystems) containing complementary DNAs for control GFP and
Elf5 were generated by routine molecular cloning techniques. The HA-tagged WT Elf5 cDNAs
was subcloned from pCMV-HA vector to pLEX plasmids using BamH1-Not1 restriction en-
zymes. Lentivirus production was performed essentially as previously described [23]. Virally
infected cells were selected with puromycin.
siRNA knockdown
For knockdown experiments, siRNA targeting the Elf5 gene (5’-AGCCCTGAGATACTACTA-
TAA-3’, catalogue number GS2001) and siRNA negative control were purchased from Qiagen.
Then, transfections were conducted using Lipofectamine RNAiMAX (Invitrogen).
Immunoblotting
Protein was extracted with RIPA lysis buffer. Protein lysates were resolved on 10% Bis-Tris
Gel, transferred to PVDF membranes, probed with HRP-linked secondary antibodies (GE
Healthcare), and visualized with ECL reagent (Thermo Scientific). Antibodies were: anti-Elf5
(Santa Cruz Biotechnology, Santa Cruz, CA), anti-E-cadherin (Abcam, Cambridge, MA), anti-
N-cadherin (Abcam), anti-Vimentin (Abcam), anti-Snail (Cell Signaling Technology, Beverly,
MA), anti-ZEB1 (Abcam).
Cell viability assay
Indicated cells were seeded in 24-well plates at a density of 5,000 per well in medium contain-
ing 10% FBS. At the indicated time point, medium was removed and serum-free medium con-
taining 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT; 0.5 mg/mL;
Sigma) was then added into each well. Four hours after incubation at 37°C, cellular formazan
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products were dissolved with acidic isopropanol, and the absorbance at 570 nm was measured
by spectrophotometry (Beckman Du640B). Six replicate wells were used for each sample at
each time point.
Migration assays
Twenty-five thousand cells were seeded into 24-well cell culture inserts with 8 mm pores (BD
Falcon). After 24–48 hr, the cells on the upper surface of the filters were removed with a cotton
swab. For visualization, cells on lower filter surfaces were fixed and stained with a toluidine
blue. Entire fields of filter were counted. Data are presented as migrated cells per field.
Sphere assay
Assays were performed as previously described with modifications [24]: 1000 cells/well were
seeded in 6-well ultra-low adhesion plates (Costar) in MEGMmedium containing 10% Serum
Replacement (KnockOut) supplemented with 1× MEM non-essential amino acid (Gibco),
20 ng/ml EGF (R&D Systems), 10 ng/ml bFGF (R&D Systems), and B27 (Gibco).
Statistical analysis
Data were reported as mean ± SE unless otherwise stated. The one-way ANOVA and Student t
test were used to analyze the differences among/between groups, respectively. SPSS (v.19, IBM,
USA) was used to assess date. P<0.05 was considered statistically significant.
Results
Elf5 mRNA expression is decreased in human bladder urothelial cancer
Relative Elf5 levels in tumor tissue from 50 UC patients were determined by qRT-PCR span-
ning 90 bp, normalized by GAPDH, and were compared with the median of 10 normal tissue
control samples (Fig. 1a). Relative Elf5 expression in normal tissues was variable within a range
of 0.39 to 10.56-fold of median levels. Tumor samples showed a decrease in Elf5 levels within a
range of 0.03 to 2.02-fold in comparison to the same control as normal tissues, with a median
of 0.40-fold lower expression (Fig. 1a). To determine whether Elf5 level showed any significant
difference among different tumor stages, the fold change in Elf5 expression was calculated. In-
termediate reduction of Elf5 mRNA was detected in NMIBC and low risk UC, while highly sig-
nificant loss of Elf5 mRNA expressions was observed in invasive (pT2–4, P<0.01, Fig. 1b) and
high risk UC (High grade pTa, CIS and invasive UC, P<0.01, Fig. 1c), compared with NMIBC
and low risk UC (low grade pTa), respectively. Based on these results, decreased Elf5 expres-
sion appears to be an important event in UC development and progression.
Elf5 protein is decreased in urothelial Cancer and associated with tumor
progression
Next, immunohistochemistry analyses of human NU and UC specimens were performed to
verify whether Elf5 expression decreased in UC on protein level. IHC staining was quantified
by counting proportion of positive-stained nucleus. In line with the mRNA data, we found Elf5
protein was stained in most normal urothelial epithelial cells (Fig. 2a). In contrast, Elf5 expres-
sion was prominently decreased in UC tissues (Fig. 2b) and almost completely lost in invasive
tumors (Fig. 2c). Then, the Elf5 expression was quantified according to tumor stages. Strong
Elf5 staining was demonstrated in NU samples with a mean of 34.10±10.21 positive rate,
whereas moderate and weak Elf5 staining were observed in pTa (19.36±1.77, P<0.05) and in-
vasive UCs (11.03±2.56, P<0.01, Fig. 2d), respectively. This suggested that Elf5 silencing may
Elf5 and EMT in Urothelial Cancer
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contribute to UC invasiveness. We further evaluated the prognostic value of Elf5 in two clinical
databases (Cohort 1A and Cohort 1B) of UC by univariate Kaplan-Meier analysis. Cohort 1A
was composed of patient with NMIBC, who received therapy of TURBT. Patients from this
group are rarely confronted with death, but always disease relapse, so the RFS was used. We
found that patients with high Elf5 expression tend to have better RFS (HR = 0.34, P = 0.001,
Fig. 2e). In contrast, patients from cohort 1B tend to be confronted with death, so the DSS was
selected. Result also revealed significant trend toward favorable prognosis for Elf5-high pa-
tients (HR = 0.49, P = 0.04, Fig. 2f). In addtion, results based on cut-offs of 5% and 15% were
also conducted (S1 Fig.). The same trends with similar results were obtained, although a non-
significantly higher DSS was detected in patients with Elf5 expression more than 15%. Overall,
our clinical data support the supposed role that Elf5 may function to oppose bladder cancer
progression.
Elf5 knockdown in epithelial-like HT1376 cells induces EMT
Previous evidence has revealed a mechanism of Elf5 inhibiting EMT in breast cancer [12]. To
investigate if Elf5 can also regulates EMT in the context of UC, we tested Elf5 expression pat-
terns in a panel of urothelial cell lines. Significantly low level of Elf5 was noticed in cell lines
characterized by mesenchymal markers (EJ and T24), mesenchymal-like cells, suggesting a po-
tential inhibitory role of Elf5 in EMT (Fig. 3a). In epithelial-like UROtsa, RT112 and HT1376
cells (identified by the high expression of epithelial markers), high level of Elf5 expression was
Fig 1. Low expression of Elf5 mRNA in human bladder UC. a, Elf5 mRNA expression is investigated in 50
UC and 10 NU tissue samples by Real-time PCR. Data are presented as mean ± standard error of the mean
(SEM). b and c, Box plots demonstrate significantly down-regulated Elf5 mRNA in both invasive (pT2–4) and
high-risk UCs (Hg-r). Horizontal lines: grouped medians. Boxes: 25–75% quartiles. Vertical lines: minimum
and maximum; NS: not significant, *P< 0.05, **P< 0.01. Low-risk UC (Lw-r): low grade pTa; Hg-r UC: High
grade pTa, CIS and invasive UC. The results shown are from two or three independent experiments.
doi:10.1371/journal.pone.0117510.g001
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demonstrated (Fig. 3a). To test the possible relationship between Elf5 and EMT, short interfer-
ing RNAs (siRNAs) were used to knock down Elf5 in epithelial-like HT1376 cells. In contrast
to the epithelial island-forming, parental cells, the siRNA-treated cells consisted of front-to-
back polarized, single cells (Fig. 3b). Similar to previously reported EMT cells [6,12], siRNA-
treated cells expressed reduction in E-cadherin and increase in N-cadherin, vimentin as well as
EMT-promoting transcription factors (eg. Snail and ZEB1) (Fig. 3c).
The sphere assay measures anchorage-independent proliferation at clonal density in vitro
has been associated with the presence of epithelial-mesenchymal state [6]. We therefore exam-
ined sphere-forming abilities of HT1376 cells to gauge their status of EMT. Relative to the pa-
rental and control siRNA (siRNA Ctrl) cells, silencing of Elf5 were 3-fold enriched in sphere-
forming cells (Fig. 3d). To test another functional hallmark of the mesenchymal state, we con-
ducted in vitro invasive assays. Elf5-knockdown cells were more invasive (18-fold compared to
parental and control cells, Fig. 3e). Furthermore, cell viability assays by MTT confirmed that
the effect of Elf5 silence on sphere-forming ability and invasiveness is not a consequence of
Fig 2. Elf5 protein is down-regulated expression and prognostic for RFS and DSS in UC. a, Representative strong Elf5 IHC staining in epithelial cells of
NU (85%). Scale bars, 100mm. b, Representative moderate Elf5 staining in non-invasive pTa tumors (30%). c, Representative weak staining in invasive NU
(<5%). d, Box plot shows Elf5 IHC staining in NU (n = 10), pTa-1 (n = 146) and invasive UCs (n = 36). Horizontal lines: grouped medians. Boxes: 25–75%
quartiles. Vertical lines: minimum and maximum; *P< 0.05, **P< 0.01. e, Kaplan-Meier curves of recurrence-free survival (RFS) according to Elf5 staining
level in primary NMIBC treated by TURBT. f, Kaplan-Meier curves of disease-specific survival (DSS) according to Elf5 staining level in UC patients after
radical cystectomy.
doi:10.1371/journal.pone.0117510.g002
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increased cell number (Fig. 3f and 3g). Together, our observations indicate that Elf5 is an inhib-
itor of EMT in UC cells.
Elf5 promotes MET in mesenchymal-like T24 cells
Meanwhile, the relationship between Elf5 and EMT was confirmed by stable overexpression of
Elf5 in mesenchymal-like T24 cells, which don’t express detectable endogenous Elf5 (Fig. 3a).
We found Elf5 overexpression effectively increased formation of epithelial island in T24 cells
(Fig. 3b). In addition, Elf5 overexpression decreased the expression level of several mesenchy-
mal cell markers, such as N-cadherin and vimentin, and increased expression of E-cadherin
(Fig. 3c). Furthermore, decreased EMT-related transcription factors were also detected in Elf5-
overexpressed T24 cells (Fig. 3c). Functionally, 5-fold sphere-forming abilities and 4-fold inva-
siveness were decreased after stable enforced-expression of Elf5 in T24 cells compare with
empty plasmid group (Fig. 3d and 3e). Elf5-induced MET was further confirmed in PC3 cells, a
mesenchymal-like prostate cancer cell line with powerful invasiveness (data not shown). Col-
lectively, our observations indicate that Elf5 is an enforcer of MET in UC cells.
Fig 3. Negative correlation between Elf5 and EMT in UC cells. a, Elf5 and EMTmarkers are detected byWestern blot analysis in urothelial cell lines.
b, Bright-phase microscopy: T24 cells transduced with vector or HA-Elf5 and HT1376 cells treated with control or Elf5 siRNA. c, Western blot analyses of Elf5
and EMTmarkers in T24 cells transduced with vector or HA-Elf5 and HT1376 cells treated with control or Elf5 siRNA. d and e, Sphere assay (n = 6) and
Migration assay (n = 3): bright-phase microscopy images and quantification of parental T24, T24-vector, T24-Elf5, and parental HT1376 as well as control
and Elf5-siRNA treated HT1376 cells. Data are presented as mean±SEM, **P< 0.01.f and g, Cell viability was determined using MTT assay. Data are
shown as mean±SEM. Six replicate wells were performed for each sample at each time point.
doi:10.1371/journal.pone.0117510.g003
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Elf5 is associated with E-cadherin and vimentin expression in human UC
To confirm the in vitro finding that the Elf5 is an inhibitor of EMT and an enforcer of MET in
UC cells, we analyzed the expression levels of Elf5, E-cadherin and vimentin by IHC in Cohort 1
patient samples (Fig. 4a). Low expression of Elf5 (e.g., case 2) is detected in 56.6% (103 of 182) of
the samples and significantly associated with low E-cadherin expression (P<0.05) and high
vimentin expression (P<0.05, Fig. 4b). These data suggest that the Elf5 is inversely associated
with mesenchymal phenotype in patients with UC.
Elf5 promoter hypermethylation inversely correlates with Elf5 mRNA
expression in human UC
After the loss expression of Elf5 in human UC tissues is acknowledged, we further go to query
the potential reasons. Recent study has demonstrated that placental Elf5 expression is down-
regulated with gestational age increase, and epigenetic regulation was proved to be as ‘gate-
keeper’ [13]. We then tested whether the activity state of Elf5 in human UC is also epigenetical-
ly controlled by its DNA methylation. Firstly, we designed primers for MSP using MethPrimer
[25]. MSP for sequence of Elf5 promoter between -1000 bp and the transcription start site
showed only one methylation in 10 NU samples (1/10, Fig. 5a). Subsequently, we analyzed
methylation status of Elf5 promoter in bladder cancer samples (Cohort 2, n = 50) (Fig. 5a), and
found a methylation frequency of 72% (36/50). To determine whether Elf5 promoter methyla-
tion contributes to Elf5 expression loss in UC, we correlated methylation and mRNA
Fig 4. Correlation between Elf5 expression and E-cadherin/vimentin expression in 182 UC patients.
A and b, IHC staining of E-cadherin and vimentin in representative cases with high (case 1) and low Elf5
expression sample (case 2). Scale bars, 100mm. b, Correlation analysis of Elf5 and EMTmarkers E-cadherin/
vimentin.
doi:10.1371/journal.pone.0117510.g004
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expression level in patients from Cohort 2. As in Fig. 1a, 10 NU tissues served as control and
their median expression rate was set to absolute value 1.0. Compared with these NU tissues,
unmethylated UC showed an almost equal Elf5 expression without considering tumor stage or
grade (median: 0.80, P = 0.08, Fig. 5b). In contrast, methylated tumor tissues showed a signifi-
cant loss of Elf5 mRNA expression (median: 0.33, P<0.01, Fig. 5b). This correlation between
loss of Elf5 mRNA expression and Elf5 promoter methylation suggests aberrant Elf5 methyla-
tion appears to be a major mechanism for Elf5 gene silencing in UC.
Targeting promoter methylation leads to Elf5 expression in UC cell lines
Promoter methylation states in human bladder cancer cell lines were analyzed using MSP. The
mesenchymal-like UC cell lines T24 and EJ revealed a hypermethylation in their promoter re-
gions, whereas hypomethylation was detected in low-invasive HT1376 cells (Fig. 6a). We
Fig 5. Negative correction between Elf5 promoter hypermethylation andmRNA expression in human
bladder samples. a, Representative MSP results of the Elf5 promoter methylation in NU, pTa and invasive
UC tissue samples as well as in negative and positive controls. U and M represent unmethylated and
methylated DNA. Bisulphite-converted unmethylated genomic, polymethylated genomic DNA and non-
template are used as controls. b, Elf5 mRNA expression by Real-time PCR is investigated according to Elf5
promoter methylation status in 10 NU and 50 UC tissue samples. Data are presented as mean ±SEM. c,
Box plot shows loss of Elf5 mRNA expression in patients with methylated Elf5 promoter. Horizontal lines:
grouped medians. Boxes: 25–75% quartiles. Vertical lines: minimum and maximum. **P< 0.01.
doi:10.1371/journal.pone.0117510.g005
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measured the level of Elf5 mRNA expression using RT-PCR assay. Doing so revealed higher
Elf5 mRNA expressions in hypomethylated cell lines (Fig. 6b). To confirmed the relationship
between promoter methylation status and Elf5 expression, we treated these UC cell lines
HT1376, J82, EJ and T24 with 5μM demethylating agent 5-AZA. Elf5 mRNA expression was
significantly restored after 5-AZA treatment except it was in hypomethylated HT1376
(Fig. 6b). In addition, Elf5 protein expression was also reversed by demethylation in T24 and
EJ cell lines (Fig. 6c and 6d).
To determine whether the newly expressed Elf5 protein is functional, EMT makers and
EMT-related transcription factors were analyzed by immunoblotting as well as invasion and
sphere formation assays. We found epithelial cell marker increased and mesenchymal cell
markers decreased after 5-AZA treatment in two mesenchymal-like UC cell lines (Fig. 6c and
6d). After 6 days of pretreatment, 5-AZA reduced 2.4-fold and 2.7-fold invasiveness in T24
and EJ cells, respectively (Fig. 6e and 6f). For sphere formation, 5-AZA respectively introduced
3.2-fold and 4.7-fold reduction in T24 and EJ cells (Fig. 6g and 6h). It is reasonable to conclude
that promoter hypermethylation contributes to loss of Elf5 expression in UC cell lines.
Fig 6. Elf5 promoter hypomethylation is associated with Elf5 expression and reversesmesenchymal
characteristics of UC cells. a, Representative MSP results illustrating the Elf5 promoter methylation status
of urothelial cell lines. b, Quantitative RT-PCR analysis the expression of Elf5 mRNA in parental UC cell lines
and 5-AZA-treated HT1376, J82, EJ and T24. NS: not significant, *P< 0.05, **P< 0.01. c and d, Western
blot analyses of Elf5 and EMTmarkers in EJ and T24 cells treated with or without 5-AZA. e and f, Migration
assay: quantification of T24 as well as EJ treated with or without 5-AZA, n = 3. g and h, Sphere assay:
quantification, n = 6. Data are presented as mean ±SEM, **P< 0.01.
doi:10.1371/journal.pone.0117510.g006
Elf5 and EMT in Urothelial Cancer
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Discussion
Three significant observations were noted in this study. First, Elf5 is a prognostic factor in pa-
tients with UC. We showed that Elf5 expression was negatively correlated with tumor grade
and stage. The early recurrence and disease-specific death were also observed in patients with
low expression of Elf5. In vitro, low Elf5 expression is associated with high invasiveness, which
can be effectively decreased by over-expressing Elf5 on purpose. Second, results from IHC
staining of UC specimens revealed a negative relation between the transcription factor Elf5 and
EMT, which is crucial for maintaining cellular traits associated with high-grade, invasiveness
and recurrence. Moreover, this observation was demonstrated in cell lines by artificial regula-
tion of Elf5 expression. Third, the Elf5 gene is hypermethylated in cancer cells, so that expan-
sion of the mesenchymal compartment and subsequent SCs is induced and sustained.
Unlike mouse, the human Elf5 gene harbours four kinds of transcript variants with two al-
ternative transcription start sites, one that identifies with orthologous start site of the mouse
gene and gives rise to the Elf5–2b isoform, while the other one covered in the intron of Elf5–2b
produces a longer variant Elf5–2a. Another transcript variant is spliced isoform of Elf5–2b
with the ets consensus motif retained lacking of the coding exons 3 and 4 (SAM/Pointed do-
main), a widespread domain in signaling and nuclear proteins [13]. In recent study, the
Elf5–2b variant was distinguished as a major form of Elf5 expressed in human, so this isoform
was chosen in our study as well as in another paper, in which Elf5 was demonstrated to be an
inhibitor of EMT in breast cancer [12].
Several studies have demonstrated that epigenetic regulation of Elf5 gene is a lineage gate-
keeper between the embryonic and trophoblast lineage compartments, as well as between basal
and luminal epithelial cells [14,26]. Here, we show that DNAmethylation functions as a barrier
of EMT in UC cells. The Elf5 promoter is CpG rich, but does not satisfy the criteria of a CpG is-
land (http://cpgislands.usc.edu). Detailed characterization of the Elf5 promoter methylation
profile by bisulphite sequencing analysis revealed that the vast majority of CpG residues in the
1-kb upstream region were methylated in cells with loss of Elf5 expression [14,26]. So, primers
discerning sequence within this region were designed in this study. In additional data analysis,
we found that the loss of Elf5 expression was not only restricted in patients with hypermethyla-
tion in Elf5 gene promoter. It is evident from the data that promoter methylation is not the
sole determinant of Elf5 expression in UC cells. Previous studies have demonstrated hormone
as an effective stimuli that can induce Elf5 expression in luminal epithelial cells, although
mechanisms underlying these effects remain to be elucidated [27,28]. Additionally, some tran-
scriptional repressors such as estrogen receptor (ER) may suppress Elf5 expression in the ab-
sence of promoter methylation, because we found that Elf5 is dominantly expressed in ER
negative luminal epithelial cells [29], and a potential DNA binding site for ER has been identi-
fied near the Elf5 gene [30].
Clinically, the troublesome problem in regard to NMIBC is the unpredictability of recurrence
and progression into muscle invasive disease, so it is necessary to look for efficient prognostic
biomarkers for patients at high risk. In this study, Kaplan-Meier survival curves indicated that
patients with positive expression of Elf5 less than 10% in UC had worse RFS after TURBT and
DSS after radical cystectomy than those with more positive Elf5 expression. Increasing evidences
suggest that anomalous EMT development triggers malignant tumor progression while Elf5 may
have an inhibitory role in this process [12]. Reported evidence additionally revealed that Elf5-in-
duced EMT inhibition is mediated by direct repression of the key inducer Snail [12]. Our study
also represents proof that Elf5 is capable of down-regulating Snail in UC cell lines.
Together, our analyses conclude for the first time that the down-regulation of Elf5 by aber-
rant promoter methylation may promote bladder cancer recurrence in patients with primary
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NMIBC treated by TURBT. Moreover, our results suggest a supposed availability of Elf5 as a
prognostic biomarker of disease-specific death for patients received radical cystectomy. In the
physiological context, Elf5 is demonstrated to be functioned as a suppressor of EMT and cancer
invasion. This may provide a new clue for novel target of UC therapy and valuable predictive
biomarker to identify patients at high risk of recurrence and death from this disease.
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